ArticleBritish journal of haematology2016

A Phase Ib Study of the combination of the Aurora Kinase Inhibitor Alisertib (MLN8237) and Bortezomib in Relapsed Multiple Myeloma.

Allison Rosenthal et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.